| Rx0000497 |
Gamida Cell Inc. |
03/26/2025 |
73441080004 |
Omisirge Cultured Fraction =8.0x10^8 TVNC and Non-Cultured Fraction =4.0x10^8 TVNC Intravenous, 1 each
1 KIT in 1 KIT (73441-800-04) * 80 mL in 1 BAG (73441-300-01) * 10 mL in 1 BAG (73441-200-01) * 40 mL in 1 BAG (73441-400-01) * 20 mL in 1 BAG (73441-1 |
01/31/2025 |
17470.00 |
512070.00 |
01/05/2039 |
Single Source Drug |
None |
None |
None |
1 |
Gamida Cell underwent a bankruptcy in May 2024 and, in that process we learned that the cost of bringing Omisirge to patients was much higher than we had originally anticipated. |
None |
No change or improvement was made. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000034 |
Genentech USA |
03/20/2025 |
50242013001 |
ALECENSA® (alectinib) 150 mg capsule, bottle of 240. 150 mg hard capsules, white, with ALE printed in black ink on the cap and 150 mg printed in black ink on the body. |
01/01/2025 |
926.94 |
19465.83 |
None |
Single Source Drug |
None |
None |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000034 |
Genentech USA |
03/20/2025 |
50242007001 |
GAZYVA® (obinutuzumab) 1,000 mg/40 mL vial. Injection: 1,000 mg/40 mL (25 mg/mL) clear, colorless to slightly brown solution in single-dose vial. |
01/01/2025 |
370.88 |
8612.72 |
None |
Single Source Drug |
None |
None |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000034 |
Genentech USA |
03/20/2025 |
50242010501 |
POLIVY® (polatuzumab vedotin-piiq) 140 mg vial. For injection: 140 mg/vial of polatuzumab vedotin-piiq as a white to grayish-white lyophilized powder in a single-dose vial for reconstitution and further dilution. |
01/01/2025 |
542.08 |
18611.41 |
None |
Single Source Drug |
None |
None |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000034 |
Genentech USA |
03/20/2025 |
50242010301 |
POLIVY® (polatuzumab vedotin-piiq) 30 mg vial. For injection: 30 mg/vial of polatuzumab vedotin-piiq as a white to grayish-white lyophilized powder in a single-dose vial for reconstitution and further dilution. |
01/01/2025 |
116.16 |
3988.17 |
None |
Single Source Drug |
None |
None |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000034 |
Genentech USA |
03/20/2025 |
50242012047 |
TNKase® (tenecteplase) 50 mg vial. For injection: 50 mg as a white to pale yellow lyophilized powder in a single-dose vial for reconstitution with co-packaged Sterile Water for Injection, USP (diluent). |
01/01/2025 |
469.66 |
8297.26 |
None |
Single Source Drug |
None |
None |
None |
1 |
We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesnt prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. |
None |
We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958250501 |
BIKTARVY bictegravir 30mg, emtricitabine 120mg, tenofovir alafenamide 15 mg tablets 30 ct |
01/01/2025 |
234.89 |
4216.10 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958250103 |
BIKTARVY bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg BLISTER PACK 30 ct |
01/01/2025 |
234.89 |
4216.10 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958250101 |
BIKTARVY bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, 30 ct |
01/01/2025 |
234.89 |
4216.10 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958090101 |
CAYSTON 75MG/VIAL KIT, 84mL |
01/01/2025 |
706.97 |
12689.57 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958110101 |
COMPLERA 200MG/25MG/300MG TABLETS, 30 ct |
01/01/2025 |
213.77 |
3836.97 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958190101 |
GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) 150/150/200/10MG TABLETS, 30 ct |
01/01/2025 |
234.89 |
4216.10 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958080205 |
LETAIRIS 10MG TABLETS 10 COUNT |
01/01/2025 |
255.29 |
4582.12 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958080201 |
LETAIRIS 10MG TABLETS 30 COUNT |
01/01/2025 |
765.86 |
13746.43 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958080105 |
LETAIRIS 5MG TABLETS 10 COUNT |
01/01/2025 |
255.29 |
4582.12 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958080101 |
LETAIRIS 5MG TABLETS 30 COUNT |
01/01/2025 |
765.86 |
13746.43 |
None |
Innovator Multiple Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958210101 |
ODEFSEY (emtricitabine, rilpivirine, and tenofovir alafenamide) 200/25/25MG TABLETS, 30 ct |
01/01/2025 |
213.77 |
3836.97 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958120101 |
STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofobir) 150/150/200/300MG TABLETS, 30 ct |
01/01/2025 |
246.41 |
4422.70 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958140101 |
TYBOST (cobicistat) 150 MG TABLETS, 30 ct |
01/01/2025 |
17.53 |
314.72 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958290102 |
VEKLURY (remdesivir 100mg) for injection, 1 ct |
01/01/2025 |
35.37 |
634.85 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958230101 |
VEMLIDY (tenofovir alafenamide) 25MG TABLETS, 30 ct |
01/01/2025 |
85.06 |
1526.65 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958170101 |
ZYDELIG (idelalisib) 100MG TABLETS, 60 ct |
01/01/2025 |
814.68 |
14622.87 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000087 |
Gilead Sciences, Inc. |
04/23/2025 |
61958170201 |
ZYDELIG (idelalisib) 150MG TABLETS, 60 ct |
01/01/2025 |
814.68 |
14622.87 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years. |
| Rx0000029 |
GlaxoSmithKline |
04/30/2025 |
49401008835 |
Benlysta Subcutaneous Solution Auto-injector 200 MG/ML CTN 4X1.0ML 1DS PF |
01/01/2025 |
145.28 |
4987.78 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000029 |
GlaxoSmithKline |
04/30/2025 |
49401008847 |
Benlysta Subcutaneous Solution Prefilled Syringe 200 MG/ML CTN 4X1.0ML 1DS PF |
01/01/2025 |
145.28 |
4987.78 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000029 |
GlaxoSmithKline |
04/30/2025 |
58160097620 |
Bexsero Intramuscular Suspension Prefilled Syringe 0.5ML PFS X10 10 PFS/CARTON |
01/01/2025 |
133.80 |
2363.76 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000029 |
GlaxoSmithKline |
04/30/2025 |
58160082311 |
Shingrix Intramuscular Suspension Reconstituted 50 MCG/0.5ML 0.5ML COMBO PK (20 VIALS) |
01/01/2025 |
176.13 |
2155.08 |
None |
Single Source Drug |
None |
None |
None |
1 |
None |
1 |
The price increase listed is not related to any identified or claimed change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |